Concord Drugs

Why is Concord Drugs Ltd falling/rising?

As of 24-Aug, Concord Drugs Ltd's stock price has risen to 76.66, reflecting a 2.21% increase, supported by an 8.89% gain over the past week and strong performance metrics. Despite a decline in investor participation, the stock remains liquid and is trading above key moving averages, indicating positive momentum.

As of 24-Aug, Concord Drugs Ltd is experiencing a rise in its stock price, currently at 76.66, which reflects an increase of 1.66 or 2.21%. This upward movement is supported by several factors. Over the past week, the stock has gained 8.89%, significantly outperforming the Sensex, which has decreased by 0.46%. Additionally, in the last two days, the stock has shown a consecutive gain, rising by 9.84% during this period.<BR><BR>Today's trading session has also seen the stock reach an intraday high of Rs 80, marking a 6.67% increase at its peak. Despite some volatility, with an intraday low of Rs 71.11, the overall performance indicates strong momentum. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive technical indicator.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 44.53% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that the recent price rise is driven by strong performance metrics rather than a lack of market interest. Overall, the combination of recent gains, positive technical indicators, and strong performance relative to the benchmark supports the rise in Concord Drugs Ltd's stock price.

Which are the latest news on Concord Drugs?

Who are in the management team of Concord Drugs?

The management team of Concord Drugs includes S Nagi Reddy (Chairman & Managing Director), K Ramchandra Reddy (Independent Director), Koni Reddy (Whole Time Director & CFO), S. Nagavenkata Hareesh (Independent Director), S. Manoj Kumar Reddy (Whole-time Director), and Summela Kasu (Independent Director).

The management team of Concord Drugs includes the following individuals:<BR><BR>1. **S Nagi Reddy** - Chairman & Managing Director<BR>2. **K Ramchandra Reddy** - Independent Director<BR>3. **Koni Reddy** - Whole Time Director & CFO<BR>4. **S. Nagavenkata Hareesh** - Independent Director<BR>5. **S. Manoj Kumar Reddy** - Whole-time Director<BR>6. **Summela Kasu** - Independent Director<BR><BR>If you need more information about their roles or contributions, feel free to ask!

What does Concord Drugs do?

Concord Drugs Ltd is an Indian pharmaceutical company established in 1995, specializing in manufacturing finished pharmaceutical formulations. As of June 2026, it reported net sales of 21 Cr and a net profit of 1 Cr, with a market cap of INR 99 Cr.

Overview:<BR>Concord Drugs Ltd is a pharmaceutical company specializing in the manufacturing of finished pharmaceutical formulations, operating within the Micro Cap category of the Pharmaceuticals & Biotechnology industry.<BR><BR>History:<BR>Established in 1995, Concord Drugs Ltd has maintained its status as a respected pharmaceutical manufacturer in India. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 21 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Jun 2026)<BR>- Market-cap: INR 99 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 45.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 0.26<BR>- Return on Equity: 2.18%<BR>- Price to Book: 2.01<BR><BR>Contact Details:<BR>- Address: Survey No 249 Brahmanapally V, Hayathnagar M Ranga Reddy Telangana : 501511<BR>- Tel: 91-40-24036379<BR>- Email: concorddrugsltd@gmail.com<BR>- Website: http://www.concorddrugs.in

Who are the peers of the Concord Drugs?

Peers of Concord Drugs include Pharmaids Pharma, Tyche Industries, Godavari Drugs, Denis Chem Lab, Mercury Labs, Veerhealth Care, Makers Labs, Sotac Pharma, and Vaishali Pharma. Concord Drugs has Below Average management risk and a 1-year return of 32.86%.

Peers: The peers of Concord Drugs are Pharmaids Pharma, Tyche Industries, Godavari Drugs, Denis Chem Lab, Mercury Labs, Veerhealth Care, Makers Labs, Sotac Pharma, and Vaishali Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab, while Average management risk is found at Tyche Industries, Godavari Drugs, and Mercury Labs, and the rest. Below Average management risk is noted for Pharmaids Pharma, Concord Drugs, Veerhealth Care, Makers Labs, Sotac Pharma, and Vaishali Pharma. Growth is Average at Veerhealth Care and the rest have Below Average growth, including Pharmaids Pharma, Tyche Industries, Godavari Drugs, Concord Drugs, Mercury Labs, Makers Labs, Sotac Pharma, and Vaishali Pharma. Excellent capital structure is seen at Tyche Industries and Denis Chem Lab, while Average capital structure is noted at Sotac Pharma, and Below Average capital structure is found at Pharmaids Pharma, Godavari Drugs, Concord Drugs, Mercury Labs, Veerhealth Care, Makers Labs, and Vaishali Pharma.<BR><BR>Return Snapshot: Veerhealth Care has the highest 1-year return at 113.30%, while Pharmaids Pharma has the lowest at -46.18%. Concord Drugs has a 1-year return of 32.86%, which is significantly higher than Pharmaids Pharma but lower than Veerhealth Care. Additionally, the six-month return is negative for Pharmaids Pharma, Tyche Industries, Godavari Drugs, Denis Chem Lab, Mercury Labs, and Makers Labs.

How big is Concord Drugs?

As of 14th August, Concord Drugs Ltd has a market capitalization of 97.00 Cr, with recent net sales of 86.12 Cr and a net profit of 2.05 Cr.

As of 14th August, Concord Drugs Ltd has a market capitalization of 97.00 Cr and is classified as a Micro Cap company.<BR><BR>In the latest four quarters, Concord Drugs reported Net Sales of 86.12 Cr and a Net Profit of 2.05 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 34.11 Cr and Total Assets of 65.14 Cr.

Should I buy, sell or hold Concord Drugs Ltd?

When is the next results date for Concord Drugs Ltd?

The next results date for Concord Drugs Ltd is 10 August 2026.

The next results date for Concord Drugs Ltd is scheduled for 10 August 2026.

Are Concord Drugs Ltd latest results good or bad?

Concord Drugs Ltd's latest results show impressive revenue growth of 264.77% and a significant profit increase, but low profit margins and a high P/E ratio raise concerns about profitability and valuation. Investors should consider these factors when assessing the company's performance.

Concord Drugs Ltd's latest results present a mixed picture. On one hand, the company reported a remarkable year-on-year revenue growth of 264.77% in Q4 FY26, with net sales reaching ₹37.90 crores. This surge is indicative of strong demand or successful order fulfillment. Additionally, net profit for the quarter increased significantly to ₹0.53 crores, reflecting a staggering 1,225.00% growth compared to the same quarter last year.<BR><BR>However, despite this impressive revenue and profit growth, there are significant concerns regarding profitability. The profit after tax (PAT) margin remains low at just 1.40%, and the operating margin has contracted to 3.93%, down from higher levels in previous periods. This suggests that while revenue is increasing, the company is facing challenges in managing costs and maintaining pricing power.<BR><BR>Furthermore, the return on equity (ROE) is quite low at 1.69%, indicating inefficiencies in capital utilization. The company's elevated valuation, trading at a P/E ratio of 191.62x, raises questions about whether the current stock price accurately reflects its fundamental performance.<BR><BR>In summary, while Concord Drugs has demonstrated exceptional revenue growth and a significant profit turnaround in the latest quarter, the underlying profitability metrics and high valuation suggest caution. Investors should weigh these factors carefully when evaluating the company's performance.

Is Concord Drugs overvalued or undervalued?

As of December 2, 2025, Concord Drugs is considered undervalued with a PE Ratio of 135.16 and a PEG Ratio of 0.63, outperforming peers like Sun Pharma and Divi's Lab, and achieving a year-to-date return of 106.29% compared to the Sensex's 8.96%.

As of 2 December 2025, Concord Drugs has moved from a fair to an attractive valuation grade. The company is currently considered undervalued, particularly in comparison to its peers in the pharmaceuticals and biotechnology sector. Notable ratios include a PE Ratio of 135.16, an EV to EBITDA of 20.90, and a PEG Ratio of 0.63, indicating potential growth relative to its price.<BR><BR>In comparison to its peers, Concord Drugs stands out with its attractive valuation, while Sun Pharma has a PE of 37.36 and an EV to EBITDA of 24.69, and Divi's Lab is even more expensive with a PE of 68.62 and an EV to EBITDA of 51.56. Despite a recent decline in stock price, Concord Drugs has significantly outperformed the Sensex over various periods, including a year-to-date return of 106.29% compared to the Sensex's 8.96%. This performance reinforces the view that the company is undervalued relative to its growth potential.

How has been the historical performance of Concord Drugs?

Concord Drugs has experienced a declining trend in net sales and profits over the past four years, with net sales at 45.25 Cr in March 2025, down from 59.06 Cr in March 2022. Despite a slight increase in some metrics in 2025, overall financial performance remains challenging.

Answer:<BR>The historical performance of Concord Drugs shows a declining trend in net sales and profits over the past four years.<BR><BR>Breakdown:<BR>Concord Drugs reported net sales of 45.25 Cr in March 2025, a slight increase from 44.93 Cr in March 2024, but a decrease from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. Total operating income mirrored this trend, remaining at 45.25 Cr in March 2025, up from 44.93 Cr in March 2024, but down from 52.09 Cr in March 2023 and 59.06 Cr in March 2022. The total expenditure, excluding depreciation, was 41.11 Cr in March 2025, up from 40.88 Cr in March 2024, but down from 47.50 Cr in March 2023 and 53.37 Cr in March 2022. Operating profit (PBDIT) was 4.14 Cr in March 2025, a slight increase from 4.05 Cr in March 2024, but lower than 4.59 Cr in March 2023 and 5.69 Cr in March 2022. Profit before tax was 0.69 Cr in March 2025, up from 0.63 Cr in March 2024, but significantly down from 1.25 Cr in March 2023 and 2.25 Cr in March 2022. Profit after tax also decreased to 0.34 Cr in March 2025 from 0.47 Cr in March 2024, 0.99 Cr in March 2023, and 1.59 Cr in March 2022. The total assets of the company increased to 65.14 Cr in March 2025 from 58.81 Cr in March 2024, while total liabilities rose to 65.14 Cr from 58.81 Cr in the same period. Cash flow from operating activities was 3.00 Cr in March 2025, showing improvement from 0.00 Cr in March 2024, while cash flow from investing activities was -2.00 Cr, and cash flow from financing activities was -1.00 Cr. Overall, the financial metrics indicate a challenging performance trajectory for Concord Drugs over the past four years.

What is the technical trend for Concord Drugs?

As of June 5, 2025, Concord Drugs is in a mildly bearish trend, with daily moving averages and weekly Bollinger Bands indicating bearish signals, while mixed signals from weekly MACD and KST, along with a neutral RSI, suggest moderate bearish strength influenced by recent price action.

As of 5 June 2025, the technical trend for Concord Drugs has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend and the weekly Bollinger Bands also showing a mildly bearish signal. While the weekly MACD and KST are mildly bullish, the monthly indicators remain bearish, suggesting mixed signals across different time frames. The RSI shows no signals, indicating a lack of momentum in either direction. Overall, the strength of the bearish trend is moderate, influenced by the recent price action and the broader market context.

Who are the top shareholders of the Concord Drugs?

The top shareholders of Concord Drugs include promoter Nagi Reddy Seelam with 28.61% ownership, while individual investors hold 43.33%. The highest public shareholder is Pradeep Kumar Jain at 1.89%, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Concord Drugs include the promoters, who hold the majority of the shares. The promoter with the highest holding is Nagi Reddy Seelam, who owns 28.61% of the company. Additionally, individual investors collectively hold 43.33% of the shares. The highest public shareholder is Pradeep Kumar Jain, with a holding of 1.89%. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company.

Has Concord Drugs declared dividend?

No Dividend History Available